OncoTherapy Science,Inc. [4564.T]
TOKYO, Apr 16 (Pulse News Wire) – Oncotherapy Science,inc. (4564.T) reported a significant exercise of its 38th series subscription rights with adjustment clauses during the period from April 1, 2026 to April 16, 2026.
A total of 1,000,000 subscription rights were exercised out of 1,000,000 issued, representing a 100% exercise rate. During this period, the company delivered 1,000,000 shares of common stock upon exercise of the subscription rights. The exercise prices ranged from ¥20.50 to ¥22.40 per share.
Notably, on April 10, 2026, 50,000 shares were transferred through self-exercise, while, another 100,000 shares were similarly transferred. As of the end of March 2026, there were 39,600,000 unexercised subscription rights outstanding. By April 16, 2026, this number had decreased to 24,600,000 unexercised subscription rights.
For more detailed information on the issuance of these subscription rights, investors should refer to the announcement published on November 21, 2025.
🟢 Confidence: High AI-translated content.